Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Press Release|Articles|August 9, 2023

Sparian Biosciences Awarded Five-Year NIH/NDA Grant for Development of SBS-518

Author(s)Jill Murphy

SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).

Sparian Biosciences announced on Aug. 8, 2023 that it has been awarded a $19 million, five-year grant to fund development of SBS-518 from investigational new drug (IND) submission through Phase I clinical development.

According to the press release, SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD). Further, StUD is a subset of substance use disorders, including cocaine and methamphetamine use disorders.

In pre-clinical efficacy assays, SBS-518 blocks the stimulant induced rise in extra-cellular dopamine and blocks cocaine and methamphetamine self-administration without itself producing self-rewarding behavior, according to the press release. Additionally, dopamine active transporters, or DAT, have been proven to be an indefinable target for therapeutics.

“Sparian was founded to develop innovative therapeutics to treat CNS disorders, particularly pain and substance use disorders,” said Jeff Reich, MD, Chief Executive Officer and Co-founder, in a press release. “StUD presents a major unmet medical and public health need for which there are currently no approved therapies. If we can successfully advance SBS-518 into the clinic, it could represent a significant step forward in the treatment of substance use disorders.”

This grant is the third NIH/NIDA grant that Sparian has received, and the company has been awarded a total of $41 million in government grants to support 3 programs. It was awarded by NIH/NIDA under the Help End Addiction Long-Term (HEAL) initiative. Its lead program, SBS1000, is now in Phase 1 clinical trials, and the dual mu opioid receptor, SBS-226, is in development for opioid use disorder (OUD).

“We are extremely proud of the ongoing support we have received from NIDA,” Reich said in a press release. “NIDA, through the HEAL initiative, has sparked a new wave of innovation and entrepreneurship dedicated to the treatment of substance use disorders. Sparian, along with our academic partners, is honored to be a trusted collaborator.”

Source: Sparian Biosciences


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.